Lou Bin, Liao Xue-Ling, Wu Man-Ping, Cheng Pei-Fang, Yin Chun-Yan, Fei Zheng
Department of Biochemistry, School of Pharmacy, Fudan University, Shanghai 200032, China.
World J Gastroenterol. 2005 Feb 21;11(7):954-9. doi: 10.3748/wjg.v11.i7.954.
To investigate the possibility of recombinant high-density lipoprotein (rHDL) being a carrier for delivering antitumoral drug to hepatoma cells.
Recombinant complex of HDL and aclacinomycin (rHDL-ACM) was prepared by cosonication of apoproteins from HDL (Apo HDL) and ACM as well as phosphatidylcholine. Characteristics of the rHDL-ACM were elucidated by electrophoretic mobility, including the size of particles, morphology and entrapment efficiency. Binding activity of rHDL-ACM to human hepatoma cells was determined by competition assay in the presence of excess native HDL. The cytotoxicity of rHDL-ACM was assessed by MTT method.
The density range of rHDL-ACM was 1.063-1.210 g/mL, and the same as that of native HDL. The purity of all rHDL-ACM preparations was more than 92%. Encapsulated efficiencies of rHDL-ACM were more than 90%. rHDL-ACM particles were typical sphere model of lipoproteins and heterogeneous in particle size. The average diameter was 31.26+/-5.62 nm by measure of 110 rHDL-ACM particles in the range of diameter of lipoproteins. rHDL-ACM could bind on SMMC-7721 cells, and such binding could be competed against in the presence of excess native HDL. rHDL-ACM had same binding capacity as native HDL. The cellular uptake of rHDL-ACM by SMMC-7721 hepatoma cells was significantly higher than that of free ACM at the concentration range of 0.5-10 microg/mL (P<0.01). Cytotoxicity of rHDL-ACM to SMMC-7721 cells was significantly higher than that of free ACM at concentration range of less than 5 microg/mL (P<0.01) and IC50 of rHDL-ACM was lower than IC50 of free ACM (1.68 nmol/L vs 3 nmol/L). Compared to L02 hepatocytes, a normal liver cell line, the cellular uptake of rHDL-ACM by SMMC-7721 cells was significantly higher (P<0.01) and in a dose-dependent manner at the concentration range of 0.5-10 microg/mL. Cytotoxicity of the rHDL-ACM to SMMC-7721 cells was significantly higher than that to L02 cells at concentration range of 1-7.5 microg/mL (P<0.01). IC50 for SMMC-7721 cells (1.68 nmol/L) was lower than that for L02 cells (5.68 nmol/L), showing a preferential cytotoxicity of rHDL-ACM for SMMC-7721 cells.
rHDL-ACM complex keeps the basic physical and biological binding properties of native HDL and shows a preferential cytotoxicity for SMMC-7721 hepatoma to normal L02 hepatocytes. HDL is a potential carrier for delivering lipophilic antitumoral drug to hepatoma cells.
研究重组高密度脂蛋白(rHDL)作为载体向肝癌细胞递送抗肿瘤药物的可能性。
通过将高密度脂蛋白载脂蛋白(Apo HDL)、阿克拉霉素(ACM)以及磷脂酰胆碱进行共超声处理,制备HDL与阿克拉霉素的重组复合物(rHDL-ACM)。通过电泳迁移率阐明rHDL-ACM的特性,包括颗粒大小、形态和包封率。在过量天然HDL存在的情况下,通过竞争试验测定rHDL-ACM与人肝癌细胞的结合活性。采用MTT法评估rHDL-ACM的细胞毒性。
rHDL-ACM的密度范围为1.063 - 1.210 g/mL,与天然HDL相同。所有rHDL-ACM制剂的纯度均超过92%。rHDL-ACM的包封率超过90%。rHDL-ACM颗粒为典型的脂蛋白球形模型,粒径不均一。通过测量110个脂蛋白直径范围内的rHDL-ACM颗粒,平均直径为31.26±5.62 nm。rHDL-ACM可结合于SMMC-7721细胞,且在过量天然HDL存在时这种结合可被竞争。rHDL-ACM具有与天然HDL相同的结合能力。在0.5 - 10 μg/mL浓度范围内,SMMC-7721肝癌细胞对rHDL-ACM的细胞摄取显著高于游离ACM(P<0.01)。在浓度低于5 μg/mL时,rHDL-ACM对SMMC-7721细胞的细胞毒性显著高于游离ACM(P<0.01),且rHDL-ACM的半数抑制浓度(IC50)低于游离ACM(1.68 nmol/L对3 nmol/L)。与正常肝细胞系L02相比,在0.5 - 10 μg/mL浓度范围内,SMMC-7721细胞对rHDL-ACM的细胞摄取显著更高(P<0.01)且呈剂量依赖性。在1 - 7.5 μg/mL浓度范围内,rHDL-ACM对SMMC-7721细胞的细胞毒性显著高于对L02细胞的毒性(P<0.01)。SMMC-7721细胞的IC50(1.68 nmol/L)低于L02细胞的IC50(5.68 nmol/L),表明rHDL-ACM对SMMC-7721细胞具有优先细胞毒性。
rHDL-ACM复合物保留了天然HDL的基本物理和生物学结合特性,对SMMC-7721肝癌细胞相对于正常L02肝细胞具有优先细胞毒性。HDL是向肝癌细胞递送亲脂性抗肿瘤药物的潜在载体。